DB-1311 — Investigational Agent
Antibody-Drug Conjugate · Phase 1/2 · DualityBio / BioNTech
Mechanism of Action
B7-H3 (CD276)-directed antibody-drug conjugate carrying a novel topoisomerase I inhibitor payload via a cleavable linker; targets B7-H3-overexpressing tumors including SCLC and NSCLC for payload delivery and bystander killing.
Investigational Indications
- Extensive-stage small cell lung cancer
- B7-H3-expressing NSCLC
- Castration-resistant prostate cancer and other solid tumors